ObsEva SA (NASDAQ:OBSV) was founded in 2012 and is headquartered in Geneva, Switzerland, with 43 full-time employees (12/31/2018). It is a clinical-stage biopharmaceutical company focusing on reproductive health between 15 and 49 years old Development and commercialization of new therapies for women with pregnancy disorders.
ObsEva SA (OBSV):
ObsEva SA is a clinical-stage biopharmaceutical company focused on developing and commercializing new therapies for women suffering from reproductive health and pregnancy disorders (infertility).
ObsEva SA is developing Linzagolix (OBE2109), an oral gonadotropin releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and severe menstrual bleeding associated with uterine fibroids in premenopausal women.
ObsEva SA is also developing Nolasiban (OBE001), an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization.
ObsEva SA is also developing OBE022, an oral and selective prostaglandin F2a (PGF2a) receptor antagonist, which is taken once a day for the prevention of preterm infants and is suitable for the age of 24 to 34 weeks of gestation.
ObsEva SA (OBSV) investment:
ObsEva SA (NASDAQ:OBSV) landed on Nasdaq at its IPO on 1/26/2017 with an issue price of US$15. It issued 6.45 million shares and raised US$96.75 million. The stock code is OBSV.